Protocol Number: 03-N-0266

Title:

Dopamine Release in Use-Dependent Plasticity in Health and Disease

Number:

03-N-0266

Summary:

This study will examine how dopamine, a brain chemical, affects motor training. Taken by mouth, dopamine can enhance motor training, especially during rehabilitation after brain damage. The study will also examine whether Sinemet, a drug containing a precursor of dopamine, can improve motor training.

Healthy normal volunteers and stroke patients between 18 and 80 years of age may be eligible for this study. Healthy volunteers must be right-handed. Stroke patients must have had a stroke that caused weakness in one hand, from which they have recovered enough to be able to move the thumb in different directions. Participants will have up to three study sessions, as follows:

Prestudy 1 (MRI, TMS with motor training)

- Session 1: Magnetic resonance imaging (MRI) of the brain. This procedure uses a strong magnetic field and radio waves to show structural and chemical changes in tissues. During the scan, the patient lies on a table in a narrow cylinder containing a magnetic field. He or she can communicate with the staff administering the test at all times.

- Session 2: Transcranial magnetic stimulation (TMS) - The subject sits in a comfortable chair with the right forearm held still at the side and the head held still by an aluminum frame. A magnetic coil is placed over the head, and a small probe is attached to the thumb to measure thumb movement. Magnetic pulses are occasionally delivered over the scalp, likely inducing a mild thumb movement. After this test, the subject takes a tablet of either Sinemet or placebo (a look-alike pill with no active ingredient). Fifty minutes after taking the pill, the subject undergoes motor training that involves performing brisk thumb movements at a rate of 1 movement per second. At the end of the training, TMS is repeated.

- Session 3: Identical to session 2, except subjects who took Sinemet in session 2 now take placebo, and vice versa.

Prestudy 2 (MRI, PET without motor training, no TMS)

- Session 1: MRI of the brain if the subject has not had one within the last 12 months.

- Session 2: Positron emission tomography (PET) scanning - This procedure provides information on brain chemistry and function. First, the subject is given either Sinemet or placebo. The subject lies on a bed in a doughnut-shaped machine with a custom-molded plastic mask placed over the face and head to support the head and hold it still during the scanning. A catheter (plastic tube) is placed in each arm-one to inject [11C]raclopride-a radioactive substance that competes with dopamine for binding in certain parts of the brain and can be detected by the PET scanner-and one to draw blood samples for measuring the level of Sinemet in the blood.

- Session 3: Identical to session 2, except subjects who took Sinemet in session 2 now take placebo, and vice versa.

Main Study (MRI, TMS, PET with motor training)

- Session 1: MRI of the brain, if one has not been done within the last 12 months.

- Session 2: TMS, followed by administration of Sinemet or placebo and PET scanning with motor training. The subject lies quietly during the first half of the PET session and performs brisk thumb movements during the second half. After completing the PET scan, the subject undergoes TMS again.

- Session 3: Identical to session 2, except subjects who took Sinemet in session 2 now take placebo, and vice versa.

Sponsoring Institute:

National Institute of Neurological Disorders and Stroke (NINDS)

Recruitment Detail

Type: Active Accrual Of New Subjects

Gender: Male & Female

Referral Letter Required: No

Population Exclusion(s): Children

Eligibility Criteria:

INCLUSION CRITERIA:

NORMAL VOLUNTEERS:

Normal neurological and physical examination.

Abstinence from alcohol one week before the study.

No medication that can influence the central nervous system for at least one week before the study because those medications may influence DA release.

Within normal range of neuropsychological and mood assessment.

No gender or ethnic preferences.

STROKE PATIENTS:

Patients with thromboembolic non-hemorrhagic lesions, located subcortical without directly affecting the basal ganglia, as documented by CT or MRI.

At least 12 months post-stroke.

Initially had a severe motor paresis (below MRC grade 2), which subsequently recovered to the point that they have a residual motor deficit but can perform the required task (thumb flexion and extension).

EXCLUSION CRITERIA:

NORMAL VOLUNTEERS AND STROKE PATIENTS:

The subjects belonging to one of the following groups will be excluded from the study:

1. Subjects with signs of parkinsonism.

2. Subjects with significant mood disturbances (score on BDI scale above 10).

3. Subjects with abnormal MRI findings on visual inspection (prominent normal variants such as mega cisterna or cavum septum pellucidum, signs of severe cortical or subcortical atrophy, brain tumors, trauma or AVMs). Stroke patients may have an ischemic territorial stroke and mild to moderate signs of vascular disease.

4. Subjects with prior exposure to neuroleptic agents or drug use.

5. Subjects with past or present neuropsychiatric illness, head trauma with loss of consciousness, epilepsy, past and present history of alcohol or substance abuse, including cigarettes, medical conditions that may alter cerebral functioning.

6. Subjects with positive urine toxicology.

7. Subjects who have pacemakers, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including heart valves and cochlear implants) or shrapnel fragments.

8. Subjects with a positive urine test.

9. Subjects with an Hb less than 12.7 mg/dl (men) or an Hb less than 11.1 mg/dl (women).

ADDITIONALLY FOR STROKE PATIENTS:

1. Patients with more than one stroke.

2. Patients with bilateral motor impairment.

3. Patients with cerebellar, cortical or brainstem lesions.

4. Patients or subjects unable to perform the task (thumb flexion and extension).

5. Patients or subjects with unstable cardiac arrhythmia.

Special Instructions: Currently Not Provided

Keywords:

Stroke

Motor Training

Positron Emission Tomograhy

Plasticity

Transcranial Magnetic Stimulation

Recruitment Keywords:

Stroke

Healthy Volunteer

HV

Conditions:

Cerebrovascular Accident

Investigational Drug(s):

11-C-Raclopride

Investigational Device(s):

None

Contacts:

Patient Recruitment and Public Liaison Office
Building 61
10 Cloister Court
Bethesda, Maryland 20892-4754
Toll Free: 1-800-411-1222
TTY: 301-594-9774 (local),1-866-411-1010 (toll free)
Fax: 301-480-9793

Electronic Mail:prpl@mail.cc.nih.gov

Citations:

Abi-Dargham A, et al., Measurement of striatal and extrastriatal dopamine D1 receptor binding potential with[11C]NNC 112 in humans: validation and reproducibility.JCereb Blood Flow Metab. 2000Feb;20(2):225-43.

Antonini A, et al., [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy onstriataldopamine D2-receptors.Neurology. 1994Jul;44(7):1325-9.

Backman L, et al., Age-related cognitive deficits mediated by changes in the striatal dopamine system. Am J Psychiatry. 2000 Apr;157(4):635-7.

• Questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.
• Technical questions regarding the Clinical Center web site, please contact the Department of Networks and Applications, CC.

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home

Warren Grant Magnuson Clinical Center (CC)
National Institutes of Health (NIH)
Bethesda, Maryland 20892. Last update: 10/23/2004